---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-230926"
form_type: "8-K"
ticker: "MAZE"
cik: "0001842295"
company_name: "Maze Therapeutics, Inc."
filed_at: "2025-10-06T23:59:59+00:00"
generated_at: "2026-05-17T04:37:27.076529+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Maze appoints ex-Incyte CEO Hervé Hoppenot as Chairman, effective Oct 6

## Summary
- Hervé Hoppenot appointed Class II director and Chairman of the Board, succeeding Charles Homcy, who remains a director.
- Hoppenot served as Incyte CEO (2014-2025) and Chairman (2015-2025); also on boards of Bicycle Therapeutics and Laboratoires Pierre Fabre.
- Receives pro rata portions of $40k director retainer and $30k Chairman retainer; granted option for 36,000 shares vesting over 36 months.

## SEC filing metadata
- accession: 0001193125-25-230926
- form_type: 8-K
- ticker: MAZE
- cik: 0001842295
- company_name: Maze Therapeutics, Inc.
- filed_at: 2025-10-06T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1842295/000119312525230926/0001193125-25-230926-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1842295/000119312525230926/d84372d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-230926
- JSON: https://secwatch.observer/filing/0001193125-25-230926.json
- Plain text: https://secwatch.observer/filing/0001193125-25-230926.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.